drugset / Trial / NCT02264119

Influence of Pantoprazole on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of Lefradafiban in Healthy Subjects

NCT02264119

Phase 1 Completed 12 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Study to assess the absorption of 20 mg Lefradafiban in two formulations, each under physiological conditions and with 40 mg Pantoprazole

Timeline

Start
1998-04
Primary completion
1998-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Lefradafiban Small molecule 20 mg Oral
Subject Pantoprazole Other / unclassified 40 mg

Indications

No indication recorded.